GSK's largest acquisition ever bolsters its lung cancer franchise with two near-approval targeted therapies.

Moderna and Oxford begin Lynch syndrome prevention trial; multiple programs progress as mRNA approaches prove durable in cancer prevention.

Mid-stage phase 2 results position elecoglipron as potential oral alternative to injectable GLP-1 treatments.

Combination therapy shows unprecedented efficacy in metastatic pancreatic cancer, sparking major investor interest.

Landmark approval marks first gene therapy for genetic hearing loss, expanding rare disease treatment options.

Allogeneic CAR-T candidate lasme-cel gains expedited pathway for relapsed/refractory B-cell acute lymphoblastic leukemia.

J&J pays $1 billion upfront for degrader antibody-conjugate platform combining protein degradation with antibody-drug conjugates.

David Sinclair-backed approach marks first human trial of therapies targeting biological age reversal.

Incyte bets on late-stage Vega Therapeutics therapy to challenge Takeda and strengthen bleeding disorder portfolio.

Gene-editing pioneer considers options after depleting substantial capital on early-stage programs.

Mixed outcomes from major pharma trials: Trodelvy's lung cancer results disappoint while Gilead's once-weekly HIV pill advances.

Roche stakes $700M upfront on novel protein-degrader approach targeting BTK enzyme for blood cancers.

Therapy expands hemophilia treatment options for pediatric patients.

Co-founded by Alnylam's John Maraganore, City advances next-generation RNAi drugs with clotting disorder lead.

Federal enforcement action targets hospitals failing to disclose pricing information to consumers.

Longevity biotech lands strategic investment and partnership to advance cellular rejuvenation therapies.

Secretive Josh Bilenker-led cancer biotech moves to go public via reverse merger with genomics firm.

Continuous glucose monitoring demonstrates utility for broader diabetes population beyond insulin users.

Diabetes experts escorted from annual meeting for distributing editorial criticizing federal research cuts.

Analysis reveals persistent supply-chain problems in US pharmaceutical market despite year-over-year improvement.

Obesity drug gains approval for new higher-strength version, expanding treatment options.

Bemotrizinol becomes the first new FDA-approved sunscreen active in over a quarter century.

Indian cancer biotech secures funding to advance CAR-T therapy platform and expand global presence.

ResMed expands beyond sleep apnea with neuromodulation device for sleep optimization.